Ebola vaccine trials are currently taking place around the world, and the need for an Ebola vaccine in West Africa has never been greater.
While public interest in Ebola might be dwindling, the epidemic continues to spread. The World Health Organization (WHO) reported the recent death toll stands at over 8 000.
Three major pharmaceuticals are taking the lead—each pursuing a different vaccine:
Johnson & Johnson – working with researchers at Oxford University, GlaxoSmithKline – working with the National Institute of Allergy and Infectious Diseases (NIAID) in the US, and Merck & Co., who has partnered with the NewLink Genetics Corporation in Iowa.
The second of these trials, through the NIAID, is currently in Phase 2, and administering the vaccine to thousands of Ebola workers.
The Director of the NIAID is Dr. Anthony Fauci, and he spoke to John about the possibility of developing a vaccine for Ebola, soon.